GnRHa用于化疗后生育力保护的循证医学研究进展  

Advances in evidence-based medical research of GnRHa for fertility protection after chemotherapy

作　　者：赵全凤 符佩姝 谷文睿 郑丹 吕宗杰[2] 杨洋 ZHAO Quanfeng;FU Peishu;GU Wenrui;ZHEN Dan;LV Zongjie;YANG Yang(Department of Pharmacy,Southwest Hospital,First Affiliated Hospital to Third Military Medical University(Army Medical University),Chongqing 400038,China;Department of Pharmacy,Chongqing Health Center for Women and Children,Chongqing 401147,China)

机构地区：[1]陆军军医大学第一附属医院药学部,重庆400038 [2]重庆市妇幼保健院药剂科,重庆401147

出　　处：《中国临床药理学与治疗学》2021年第12期1449-1454,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：重庆市技术创新与应用发展专项面上项目(cstc2019jscxmsxmX0096)。

摘　　要：随着肿瘤患者长期生存率提高,年轻肿瘤患者化疗后生育力保护的要求日益凸显。早期研究显示促性腺激素释放激素激动剂(GnRHa)具有一定的生育力保护作用,但近年来相关研究显示其保护作用存在争议。本文综述GnRHa用于常见肿瘤患者生育力保护的临床研究,挖掘其循证医学证据,以期为临床合理用药提供参考。With an improvement in the long-term survival rates of cancer patients, the requirements for fertility protection of young cancer patients after chemotherapy are increasingly prominent. Early studies have shown that gonadotropin-releasing hormone agonist(GnRHa) has a protective effect on fertility. But in recenct year, relevant studies have shown that its protective effect is controversial. This article reviews the clinical researches of GnRHa for fertility protection in patients with common tumors, and explores its evidence-based medicine, in the hope of providing references for reasonable clinical application.

关 键 词：促性腺激素释放激素激动剂 生育力保护 化疗 循证医学 

分 类 号：R969.3[医药卫生—药理学]